Abstract:Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.

Lactylation-driven FTO-mediated m6A modification of CDK2 aggravates diabetic microvascular anomalies

Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy

N6-Methyladenosine Demethylase FTO Controlsmacrophage Homeostasis in Diabetic Vasculopathy

FTO Fuels Diabetes-Induced Vascular Endothelial Dysfunction Associated with Inflammation by Erasing M6a Methylation of TNIP1.

N6-methyladenosine demethylase fat mass and obesity-associated protein suppresses hyperglycemia-induced endothelial cell injury by inhibiting reactive oxygen species formation via autophagy promotion

Comprehensive analysis of the m6A demethylase FTO in endothelial dysfunction by MeRIP sequencing

FTO regulates ocular angiogenesis via m6A-YTHDF2-dependent mechanism

Circular Ribonucleic Acid circFTO Promotes Angiogenesis and Impairs Blood–Retinal Barrier Via Targeting the miR-128-3p/Thioredoxin Interacting Protein Axis in Diabetic Retinopathy

FTO-mediated m6A modification of serum amyloid A2 mRNA promotes podocyte injury and inflammation by activating the NF-κB signaling pathway

FTO Elicits Tumor Neovascularization in Cancer-Associated Fibroblasts Through Eliminating M6a Modifications of Multiple Pro-Angiogenic Factors

O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy

FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m 6 A modifications of multiple pro-angiogenic factors

FTO mediates the diabetic kidney disease progression through regulating the m6A modification of NLRP3

Integrated Metabolomics and Transcriptomics Reveal Metabolic Patterns in Retina of STZ-Induced Diabetic Retinopathy Mouse Model

KAT1 triggers YTHDF2-mediated ITGB1 mRNA instability to alleviate the progression of diabetic retinopathy

N 6-Methyladenosine demethylase FTO controls macrophage homeostasis in diabetic vasculopathy

LncRNA TDRG1-Mediated Overexpression of VEGF Aggravated Retinal Microvascular Endothelial Cell Dysfunction in Diabetic Retinopathy

DNMT1-mediated lncRNA MEG3 methylation accelerates endothelial-mesenchymal transition in diabetic retinopathy through the PI3K/Akt/mTOR signaling pathway

Knockdown of lncRNA TUG1 alleviates diabetic retinal vascular dysfunction through regulating miR-524-5p/FGFR2

The hsa_circ_0004805/hsa_miR-149-5p/ TGFB2 axis plays critical roles in the pathophysiology of diabetic retinopathy in vitro and in vivo

N6-methyladenosine Demethylase FTO Impairs Hepatic Ischemia–reperfusion Injury Via Inhibiting Drp1-mediated Mitochondrial Fragmentation